Trial Profile
A phase I study to evaluate the efficacy and safety of MVA-BN RSV vaccine in paediatric patients
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase I
Latest Information Update: 25 Jul 2023
Price :
$35
*
At a glance
- Drugs MVA-BN RSV (Primary)
- Indications Respiratory syncytial virus infections
- Focus Adverse reactions
- 22 Jul 2023 Status changed from planning to withdrawn prior to enrolment according to Bavarian Nordic media release.
- 26 May 2016 New trial record
- 23 May 2016 According to a Bavarian Nordic media release, the company plans to initiate this trial in 2017.